ATE281468T1 - Multifunktionelle molekuläre komplexe für den gen-transfer in zellen - Google Patents

Multifunktionelle molekuläre komplexe für den gen-transfer in zellen

Info

Publication number
ATE281468T1
ATE281468T1 AT95935213T AT95935213T ATE281468T1 AT E281468 T1 ATE281468 T1 AT E281468T1 AT 95935213 T AT95935213 T AT 95935213T AT 95935213 T AT95935213 T AT 95935213T AT E281468 T1 ATE281468 T1 AT E281468T1
Authority
AT
Austria
Prior art keywords
cells
gene transfer
nucleic acid
multifunctional molecular
acid composition
Prior art date
Application number
AT95935213T
Other languages
English (en)
Inventor
Raymond H Boutin
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE281468T1 publication Critical patent/ATE281468T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Botany (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Steroid Compounds (AREA)
AT95935213T 1994-09-28 1995-09-28 Multifunktionelle molekuläre komplexe für den gen-transfer in zellen ATE281468T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/314,060 US5837533A (en) 1994-09-28 1994-09-28 Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
PCT/US1995/012502 WO1996010038A1 (en) 1994-09-28 1995-09-28 Multifunctional molecular complexes for gene transfer to cells

Publications (1)

Publication Number Publication Date
ATE281468T1 true ATE281468T1 (de) 2004-11-15

Family

ID=23218392

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95935213T ATE281468T1 (de) 1994-09-28 1995-09-28 Multifunktionelle molekuläre komplexe für den gen-transfer in zellen

Country Status (9)

Country Link
US (5) US5837533A (de)
EP (1) EP0789708B1 (de)
JP (1) JP3925815B2 (de)
AT (1) ATE281468T1 (de)
CA (1) CA2201396C (de)
DE (1) DE69533725T2 (de)
ES (1) ES2231791T3 (de)
PT (1) PT789708E (de)
WO (1) WO1996010038A1 (de)

Families Citing this family (224)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795870A (en) * 1991-12-13 1998-08-18 Trustees Of Princeton University Compositions and methods for cell transformation
US5670347A (en) 1994-05-11 1997-09-23 Amba Biosciences Llc Peptide-mediated gene transfer
US5837533A (en) * 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5767099A (en) * 1994-12-09 1998-06-16 Genzyme Corporation Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules
US5719131A (en) * 1994-12-09 1998-02-17 Genzyme Corporation Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
US5948767A (en) * 1994-12-09 1999-09-07 Genzyme Corporation Cationic amphiphile/DNA complexes
US6383814B1 (en) 1994-12-09 2002-05-07 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US6331524B1 (en) 1994-12-09 2001-12-18 Genzyme Corporation Organ-specific targeting of cationic amphiphile / DNA complexes for gene therapy
US5650096A (en) * 1994-12-09 1997-07-22 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5747471A (en) * 1994-12-09 1998-05-05 Genzyme Corporation Cationic amphiphiles containing steroid lipophilic groups for intracellular delivery of therapeutic molecules
US5910487A (en) * 1994-12-09 1999-06-08 Genzyme Corporation Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules
US5840710A (en) * 1994-12-09 1998-11-24 Genzyme Corporation Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
US6071890A (en) * 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6008202A (en) 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
EP0874910A4 (de) * 1995-06-07 1999-04-21 Life Technologies Inc Durch peptide erhöhte kationische lipid transfektionen
US20030069173A1 (en) * 1998-03-16 2003-04-10 Life Technologies, Inc. Peptide-enhanced transfections
US6051429A (en) * 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
FR2736642B1 (fr) * 1995-07-10 1997-09-12 Pasteur Institut Immunovecteurs, notamment anticorps et fragments d'anticorps utilisables pour le transport intracellulaire et intranucleaire de principes biologiquement actifs notamment d'haptenes, de proteines et d'acides nucleiques
FR2741066B1 (fr) * 1995-11-14 1997-12-12 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
US7002027B1 (en) 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
US6392069B2 (en) 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
FR2744453B1 (fr) * 1996-02-05 1998-07-10 Transgene Sa Composes lipopolyamines, compositions pharmaceutiques en comprenant, vecteurs de transfert d'acide nucleique et procede de preparation
US6077834A (en) * 1996-02-09 2000-06-20 Cheng; Pi-Wan Receptor ligand-facilitated delivery of biologically active molecules
AU2911197A (en) * 1996-05-24 1998-01-05 Imperial College Of Science, Technology And Medicine Polycationic sterol derivatives as transfection agents
US5935936A (en) * 1996-06-03 1999-08-10 Genzyme Corporation Compositions comprising cationic amphiphiles and co-lipids for intracellular delivery of therapeutic molecules
WO1998000554A1 (en) 1996-07-03 1998-01-08 Genetics Institute, Inc. Protease fmh-1, an ice/ced-like protease
CN1181422A (zh) * 1996-10-31 1998-05-13 上海市肿瘤研究所 与生长因子受体结合的多肽所构建的基因转移载体
GB9623051D0 (en) * 1996-11-06 1997-01-08 Schacht Etienne H Delivery of DNA to target cells in biological systems
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US5925628A (en) * 1997-03-31 1999-07-20 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5912239A (en) * 1997-04-04 1999-06-15 Genzyme Corporation Imidazole-containing cationic amphiphiles for intracellular delivery of therapeutic molecules
US5948925A (en) * 1997-05-06 1999-09-07 Genzyme Corporation Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids
US5952516A (en) * 1997-05-08 1999-09-14 Genzyme Corporation Cationic amphiphiles containing multiplesteroid lipophilic groups
US5942634A (en) * 1997-05-09 1999-08-24 Genzyme Corporation Cationic amphiphiles for cell transfections
TW586934B (en) * 1997-05-19 2004-05-11 Sumitomo Pharma Immunopotentiating composition
US6818627B1 (en) 1997-08-14 2004-11-16 The Trustees Of The University Of Pennsylvania Functional fragments of HIV-1 Vpr protein and methods of using the same
EP2218732A1 (de) 1997-11-28 2010-08-18 Merck Serono Biodevelopment Genomsequenz von Chlamydia trachomatis sowie Polypeptide, Fragmente davon und deren Verwendung, insbesondere zur Diagnose, Prävention und Behandlung einer Infektion
US6919076B1 (en) 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
US6958148B1 (en) 1998-01-20 2005-10-25 Pericor Science, Inc. Linkage of agents to body tissue using microparticles and transglutaminase
FR2774394B1 (fr) * 1998-01-30 2002-04-26 Rhone Poulenc Rorer Sa Composes transfectants sensibles aux conditions reductrices, compositions pharmaceutiques les contenant, et leurs applications
EP1049793B1 (de) 1998-01-30 2005-10-12 Aventis Pharma S.A. Für reduzierende bedingungen empfindliche transfektions-verbindungen, pharmazeutische zusammensezungen die diese enthalten und deren verwendung.
CA2792479A1 (en) 1998-02-27 1999-09-02 The Trustees Of The University Of Pennsylvania Vaccines, immunotherapeutics and methods for using the same
AU768542C (en) * 1998-04-08 2004-06-17 Celltech R & D Limited Lipids
EP0996739A2 (de) * 1998-05-06 2000-05-03 Transgene S.A. Verbesserungen der gentherapie durch verwendung der zusammensetzungen die ein polynukleotid und ein nukleasehemmer oder interleukin-10 enthalten
EP0963758A3 (de) * 1998-05-07 2000-03-22 Universiteit Gent Synthetische polyamiosaure Komplexen zur Verabreichung von Nukleinsäuren zur Zielzellen
US6596699B2 (en) 1998-09-22 2003-07-22 Biosurface Engineering Technologies, Inc. Nucleic acid coating compositions and methods
EP1829856A3 (de) 1998-11-12 2009-02-25 Invitrogen Corporation Transfektionsreagenzien
CA2353816C (en) * 1998-12-14 2010-06-01 Dendreon Corporation Compositions and methods for enhancement of major histocompatibility complex class i restricted antigen presentation
US7148324B1 (en) 1998-12-14 2006-12-12 Dendreon Corporation Compositions and methods for enhancement of major histocompatibility complex class I restricted antigen presentation
AU762006B2 (en) 1998-12-24 2003-06-19 Ucb Peptidic product, process and composition
WO2000044914A1 (en) * 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
CA2370628A1 (en) 1999-04-21 2000-10-26 American Home Products Corporation Methods and compositions for inhibiting the function of polynucleotide sequences
DE60044247D1 (de) * 1999-04-30 2010-06-02 Inst Rech S Cliniques De Montr Humane cd80-mutante und zusammensetzungen und methoden zu deren herstellung und verwendung
AUPQ014799A0 (en) * 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using polymers
AUPQ014699A0 (en) * 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using nanoparticles
WO2000067825A1 (en) 1999-05-07 2000-11-16 Microheart, Inc. Apparatus and method for delivering therapeutic and diagnostic agents
AU5595300A (en) 1999-06-02 2000-12-18 Microheart, Inc. Devices and methods for delivering a drug
US7147633B2 (en) 1999-06-02 2006-12-12 Boston Scientific Scimed, Inc. Method and apparatus for treatment of atrial fibrillation
GB9914045D0 (en) * 1999-06-16 1999-08-18 Smithkline Beecham Plc Novel compounds
GB9914085D0 (en) * 1999-06-16 1999-08-18 Smithkline Beecham Plc New use
GB9918670D0 (en) 1999-08-06 1999-10-13 Celltech Therapeutics Ltd Biological product
AU7105300A (en) 1999-09-03 2001-04-10 Lifebeam Technologies, Inc. Optical system for rapid polymer analysis
US6312474B1 (en) * 1999-09-15 2001-11-06 Bio-Vascular, Inc. Resorbable implant materials
WO2001041784A1 (en) * 1999-12-09 2001-06-14 The Regents Of The University Of California Methods and compositions for use in the treatment of filovirus mediated disease conditions
US6933108B2 (en) * 1999-12-09 2005-08-23 The Regents Of The University Of California Methods and compositions for use in the treatment of filovirus mediated disease conditions
WO2001045749A1 (en) * 1999-12-22 2001-06-28 The Trustees Of The University Of Pennsylvania Cosmid dna constructs and methods of making and using the same
CN101041079A (zh) * 1999-12-30 2007-09-26 诺瓦提斯公司 用于基因治疗的新的胶体合成载体
US7355019B2 (en) * 2000-06-06 2008-04-08 Sibtech, Inc. Cysteine-containing peptide tag for site-specific conjugation of proteins
IL153576A0 (en) * 2000-07-14 2003-07-06 Univ Pennsylvania Dna vaccines encoding hiv accessory proteins
ATE381351T1 (de) * 2000-07-27 2008-01-15 Univ Pennsylvania Anwendung des herpes simplex virus glykoproteins- d zur unterdrückung von immunantworten
EP1322338A4 (de) * 2000-10-04 2005-04-13 Univ Pennsylvania Zusammensetzungen und methoden zur verwendung des kapsidproteins aus flaviviren oder pestviren
US6897067B2 (en) * 2000-11-03 2005-05-24 Regents Of The University Of Michigan Surface transfection and expression procedure
EP1330516B1 (de) * 2000-11-03 2007-01-17 The Regents Of The University Of Michigan Oberflächentransfektion und expressionsverfahren
US6902933B2 (en) * 2000-11-03 2005-06-07 Regents Of The University Of Michigan Surface transfection and expression procedure
US20020188023A1 (en) * 2000-12-12 2002-12-12 Michael Jorgensen Compound
PT1372708E (pt) 2001-02-13 2008-09-29 Us Gov Sec Army Vacina para imunização transcutânea
JP2004533236A (ja) * 2001-04-13 2004-11-04 ワイエス 化膿性連鎖球菌（Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｙｏｇｅｎｅｓ）の表面タンパク質
US20070128229A1 (en) * 2002-04-12 2007-06-07 Wyeth Surface proteins of Streptococcus pyogenes
CN1636062A (zh) 2001-04-16 2005-07-06 惠氏控股公司 编码多肽抗原的新肺炎链球菌可读框及其应用
GB0120022D0 (en) 2001-08-16 2001-10-10 Photobiotics Ltd Conjugate
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US20030138407A1 (en) * 2001-11-02 2003-07-24 Patrick Lu Therapeutic methods for nucleic acid delivery vehicles
TR201910060T4 (tr) 2001-12-20 2019-07-22 Merck Sharp & Dohme SYN3 bileşimleri ve yöntemleri.
US7026166B2 (en) * 2002-01-22 2006-04-11 Chiron Corporation Fluorogenic dyes
AU2003217355B2 (en) * 2002-02-07 2009-04-23 University Of Utah Research Foundation Method for creating and using a treatment protocol
US20050222064A1 (en) * 2002-02-20 2005-10-06 Sirna Therapeutics, Inc. Polycationic compositions for cellular delivery of polynucleotides
MXPA04008890A (es) * 2002-03-15 2005-10-18 Wyeth Corp Mutantes de la proteina p4 de haemophilus influenzae no tipicable con actividad enzimatica reducida.
US20040180438A1 (en) 2002-04-26 2004-09-16 Pachuk Catherine J. Methods and compositions for silencing genes without inducing toxicity
CA2385110A1 (en) * 2002-05-06 2003-11-06 University Of British Columbia Co-expression system for large functional proteins
AU2003221581A1 (en) * 2002-05-06 2003-11-17 University Of British Columbia Expression system for large functional proteins
AU2003266014B2 (en) 2002-05-06 2009-05-14 Alnylam Pharmaceuticals, Inc. Methods for delivery of nucleic acids
WO2004011624A2 (en) * 2002-07-31 2004-02-05 Nucleonics, Inc. Double stranded rna structures and constructs, and methods for generating and using the same
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
US7144588B2 (en) 2003-01-17 2006-12-05 Synovis Life Technologies, Inc. Method of preventing surgical adhesions
US7704756B2 (en) * 2003-01-21 2010-04-27 Novartis Vaccines And Diagnostics, Inc. Fluorogenic dyes
CN101239190B (zh) * 2003-01-27 2013-09-25 恩多塞特公司 维生素受体结合递药缀合物
US7355056B2 (en) 2003-06-04 2008-04-08 Canji, Inc. Transfection agents
WO2004108088A2 (en) * 2003-06-04 2004-12-16 Canji, Inc. Methods and compositions for interferon therapy
EP2284268A3 (de) 2003-06-12 2012-05-30 Alnylam Pharmaceuticals Inc. Konservierte HBV- und HCV-Sequenzen zur Genausschaltung
CA2529752A1 (en) * 2003-06-20 2005-09-15 The Regents Of The University Of California Polypeptide transduction and fusogenic peptides
WO2005040388A2 (en) * 2003-08-22 2005-05-06 Nucleonics Inc. Eukariotic expression systems for expression of inhibitory rna in multiple intracellular compartments
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
WO2005056752A2 (en) 2003-10-24 2005-06-23 Gencia Corporation Methods and compositions for delivering polynucleotides
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US20090208478A1 (en) * 2003-10-24 2009-08-20 Gencia Corporation Transducible polypeptides for modifying metabolism
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US7740861B2 (en) * 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
US7985581B2 (en) 2004-08-23 2011-07-26 Alnylam Pharmaceuticals, Inc. Multiple RNA polymerase III promoter expression constructs
ES2375995T3 (es) * 2004-09-17 2012-03-08 University Of Massachusetts Composiciones y sus usos para deficiencias de enzima lisosomal.
EP2772541A3 (de) 2004-09-24 2014-09-24 Alnylam Pharmaceuticals Inc. Targeting von Zwischenprodukten zur Gegenstrangreplikation von Hepatitis C Virus durch RNAi
BRPI0516974A (pt) 2004-10-21 2008-09-30 Wyeth Corp composição imunogênica compreendendo um polipeptìdeo; um método para induzir uma resposta imune contra staphylococcus epidermidis; um método para induzir uma resposta imune contra staphylococcus aureus; um método para a detecção e/ou identificação de staphylococcus epidermidis; um método para a detecção e/ou identificação de anticorpos para staphylococcus epidermidis
DE602005027747D1 (de) 2004-12-22 2011-06-09 Alnylam Pharmaceuticals Inc Zum gen-silencing geeignete konservierte hbv- und hcv-sequenzen
US20090182019A1 (en) * 2005-04-18 2009-07-16 The Johns Hopkins University Histone deacetylase inhibitors
US20070087045A1 (en) * 2005-10-14 2007-04-19 Industrial Technology Research Institute Lipid carrier and method of preparing the same
EP1948245B1 (de) * 2005-10-24 2011-10-05 University of Massachusetts Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
US9259463B2 (en) 2006-01-16 2016-02-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Chlamydia vaccine
CA2649182C (en) 2006-04-07 2018-01-02 The Board Of Regents Of The University Of Texas System Methods and compositions related to adenoassociated virus-phage particles
DK2548438T3 (en) 2006-11-08 2015-10-19 Veritas Bio LLC IN VIVO SUBMITTING DOUBLE-STRENGTH RNA TO A CELL
EP1935434A1 (de) * 2006-12-19 2008-06-25 Novosom AG Konstruktion und Verwendung von transfektionsverstärkenden Elementen
EP2124895A2 (de) * 2006-12-22 2009-12-02 Imuthes Limited Lipide und ihre verwendung als nichtvirales abgabevehikel
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
US20100144848A1 (en) * 2007-01-24 2010-06-10 Syddansk Universitet Dna controlled assembly of lipid membranes
US8889117B2 (en) * 2007-02-15 2014-11-18 Yale University Modular nanoparticles for adaptable vaccines
US10265407B2 (en) 2007-02-15 2019-04-23 Yale University Modular nanodevices for smart adaptable vaccines
WO2008109347A2 (en) * 2007-03-02 2008-09-12 Yale University Methods for ex vivo administration of drugs to grafts using polymeric nanoparticles
LT2494993T (lt) 2007-05-04 2018-12-27 Marina Biotech, Inc. Aminorūgščių lipidai ir jų panaudojimas
CA2687115A1 (en) * 2007-05-16 2008-11-20 Mat Malta Advanced Technologies Limited Treatment and prevention of influenza
US7973019B1 (en) 2007-10-03 2011-07-05 Alcon Research, Ltd. Transferrin/transferrin receptor-mediated siRNA delivery
EP2222283A2 (de) * 2007-10-29 2010-09-01 University of Massachusetts Zur freisetzung von nukleinsäuren (sirna) mit hefe-zellwandproteinen verkapselte mehrlagige nanopatikel
US7928189B2 (en) * 2008-05-05 2011-04-19 Ottawa Health Research Institute PCSK9 polypeptide fragment
RU2010151562A (ru) 2008-06-20 2012-07-27 ВАЙЕТ ЭлЭлСи (US) Композиции и способы применения orf1358 из бета-гемолитических стрептококковых штаммов
WO2010008582A2 (en) 2008-07-18 2010-01-21 Rxi Pharmaceuticals Corporation Phagocytic cell drug delivery system
US20110111044A1 (en) * 2008-07-31 2011-05-12 Enzon Pharmaceuticals, Inc. Nanoparticle compositions for nucleic acids delivery system
EP2340309A2 (de) 2008-09-22 2011-07-06 Rxi Pharmaceuticals Corporation Neutrale nanotransporter
CN107050442B (zh) * 2008-11-05 2022-09-13 惠氏有限责任公司 用于预防β-溶血链球菌(BHS)疾病的多组分免疫原性组合物
US9493774B2 (en) 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
EP2387609B1 (de) 2009-01-13 2018-05-16 Stembios Technologies, Inc. Nichtembryonische stammzellen und ihre verwendung
CN102459576B (zh) 2009-04-27 2015-04-01 渥太华医院研究所 用于调节干细胞的组合物和方法及其应用
CN102459301B (zh) 2009-05-05 2016-01-20 米拉根医疗公司 亲脂性多聚核苷酸缀合物
AU2010258875A1 (en) 2009-06-08 2012-01-19 Miragen Therapeutics Chemical modification motifs for miRNA inhibitors and mimetics
WO2011084721A2 (en) * 2009-12-21 2011-07-14 Agave Pharma Inc Cationic molecule and method of use
EP3023495B1 (de) * 2010-02-24 2019-05-08 Arrowhead Pharmaceuticals, Inc. Zusammensetzung für die gezielte freisetzung von sirna
TWI686202B (zh) 2010-08-04 2020-03-01 幹細胞生物科技公司 體幹細胞
RU2580620C2 (ru) 2010-08-23 2016-04-10 ВАЙЕТ ЭлЭлСи СТАБИЛЬНЫЕ КОМПОЗИЦИИ АНТИГЕНОВ Neisseria meningitidis rLP2086
WO2012032489A1 (en) 2010-09-10 2012-03-15 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
US9416360B2 (en) 2010-11-05 2016-08-16 MiRagen Therapeutics, Inc. Base modified oligonucleotides
EP2643454A4 (de) 2010-11-24 2014-05-21 Hong Gao Erweiterung hämatopoetischer stammzellen
AR084319A1 (es) 2010-12-15 2013-05-08 Miragen Therapeutics INHIBIDORES DE microARN (miARN O miR) QUE COMPRENDEN NUCLEOTIDOS BLOQUEADOS
JP2014515024A (ja) 2011-04-12 2014-06-26 ベス イスラエル デアコネス メディカル センター， インコーポレイテッド マイクロｒｎａ阻害剤および疾患におけるその使用
CA2844577A1 (en) 2011-09-13 2013-03-21 Ottawa Hospital Research Institute Microrna inhibitors
AU2012321103B2 (en) 2011-09-16 2016-05-12 Ottawa Hospital Research Institute Wnt7a compositions and methods of using the same
BR112014006321A2 (pt) 2011-09-16 2017-04-11 Fate Therapeutics Inc composições de wnt e usos terapêuticos de tal composição
TWI571513B (zh) 2011-09-28 2017-02-21 幹細胞生物科技股份有限公司 體幹細胞及其製備方法
WO2013051718A1 (ja) 2011-10-07 2013-04-11 国立大学法人三重大学 キメラ抗原受容体
ES2698076T3 (es) * 2011-10-07 2019-01-30 Isd Immunotech Aps Identificación de los dominios inmunosupresores en las proteínas de fusión de los virus de ARN con envoltura
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CA2865745C (en) 2012-03-09 2018-01-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2013163176A1 (en) 2012-04-23 2013-10-31 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
CN104685056A (zh) 2012-06-21 2015-06-03 米拉根医疗股份有限公司 包含锁核酸基序的基于寡核苷酸的抑制剂
EP2956473A4 (de) * 2013-02-15 2016-07-20 New York Blood Ct Inc Oligomere immunogene influenza-zusammensetzungen
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
CN105188715B (zh) 2013-03-15 2018-12-25 米拉根医疗股份有限公司 Mir-145的锁定核酸抑制剂及其用途
KR20150131365A (ko) 2013-03-15 2015-11-24 미라젠 세러퓨틱스 인코포레이티드 브리지드 바이사이클릭 뉴클레오시드
KR102233251B1 (ko) 2013-04-03 2021-03-26 엔-폴드 엘엘씨 신규 나노입자 조성물
US9428748B2 (en) 2013-06-17 2016-08-30 Hong Gao Method of expanding hematopoietic stem cells
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
US10172916B2 (en) 2013-11-15 2019-01-08 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating heart failure with agonists of hypocretin receptor 2
WO2015074010A2 (en) 2013-11-18 2015-05-21 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for cardiac regeneration
WO2016011203A1 (en) 2014-07-15 2016-01-21 Life Technologies Corporation Compositions with lipid aggregates and methods for efficient delivery of molecules to cells
US9752144B2 (en) 2014-08-04 2017-09-05 MiRagen Therapeutics, Inc. Inhibitors of MYH7B and uses thereof
WO2016040373A1 (en) 2014-09-08 2016-03-17 MiRagen Therapeutics, Inc. Mir-29 mimics and uses thereof
CN107636003A (zh) 2015-01-20 2018-01-26 米拉根医疗股份有限公司 miR‑92抑制剂及其用途
AU2016221318B2 (en) 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2016179034A2 (en) 2015-05-01 2016-11-10 The Trustees Of The University Of Pennsylvania Methods and compositions for stimulating immune response using potent immunostimulatory rna motifs
WO2016197024A2 (en) 2015-06-05 2016-12-08 MiRagen Therapeutics, Inc. Mir-155 inhibitors for treating cutaneous t cell lymphoma (ctcl)
AU2016301196B2 (en) 2015-08-06 2022-09-08 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation
WO2017087486A1 (en) 2015-11-16 2017-05-26 Ohio State Innovation Foundation Methods and compositions for treating disorders and diseases using survival motor neuron (smn) protein
US11052111B2 (en) 2015-12-08 2021-07-06 Chimera Bioengineering, Inc. Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
WO2017157950A1 (en) 2016-03-15 2017-09-21 Johann Wolfgang Goethe-Universität Light inducible antisense oligonucleotides for in vivo application
US11814627B2 (en) 2016-06-20 2023-11-14 The Board Of The Leland Stanford Junior University Circular RNAs and their use in immunomodulation
UY37376A (es) 2016-08-26 2018-03-23 Amgen Inc Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso
EP4342978A3 (de) 2016-09-01 2024-07-03 Chimera Bioengineering Inc. Goldoptimierte car-t-zellen
ES2659845B1 (es) 2016-09-19 2019-01-04 Univ Valencia Modulación de microRNAs contra la distrofia miotónica tipo 1 y antagonistas de microRNAs para ello
US20180179553A1 (en) 2016-12-14 2018-06-28 Ligandal, Inc. Compositions and methods for nucleic acid and/or protein payload delivery
US10183070B2 (en) 2017-01-31 2019-01-22 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP3580212A4 (de) 2017-02-08 2021-03-17 Dana Farber Cancer Institute, Inc. Regulierung von chimären antigenrezeptoren
JP7167059B2 (ja) 2017-04-19 2022-11-08 フィオ ファーマシューティカルズ コーポレーション 核酸化合物の局所送達
UY38003A (es) 2017-12-12 2019-06-28 Amgen Inc Construcciones de arni para inhibir la expresión de pnpla3 y métodos de uso de las mismas
US11753639B2 (en) 2018-03-14 2023-09-12 Beth Israel Deaconess Medical Center Micro-RNA and obesity
US20240216509A1 (en) 2018-05-07 2024-07-04 Children's Hospital Medical Center Chimeric polypeptides, nucleic acid molecules, cells, and related methods
KR20210102932A (ko) 2018-12-10 2021-08-20 암젠 인크 Pnpla3 발현을 억제하기 위한 rnai 작제물 및 이의 사용 방법
CN119061010A (zh) 2018-12-10 2024-12-03 美国安进公司 经化学修饰的RNAi构建体及其用途
JPWO2020213724A1 (de) 2019-04-19 2020-10-22
AR119061A1 (es) 2019-05-30 2021-11-17 Amgen Inc CONSTRUCCIONES DE ARNi PARA INHIBIR LA EXPRESIÓN DE SCAP Y MÉTODOS DE USO DE LAS MISMAS
JPWO2020246563A1 (de) 2019-06-05 2020-12-10
JP7699552B2 (ja) 2019-07-03 2025-06-27 ファクター バイオサイエンス インコーポレイテッド カチオン性脂質及びその使用
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods
CA3150758A1 (en) 2019-08-13 2021-02-18 Amgen Inc. Rnai constructs for inhibiting slc30a8 expression and methods of use thereof
EP4034157A1 (de) 2019-09-27 2022-08-03 Pfizer Inc. Neisseria-meningitidis-zusammensetzungen und verfahren dafür
AU2020399636A1 (en) 2019-12-09 2022-06-02 Amgen Inc. RNAi constructs and methods for inhibiting LPA expression
US20230088509A1 (en) 2020-05-20 2023-03-23 St. Jude Children's Research Hospital Detection of alzheimer's disease using specific biomarkers
CA3184345A1 (en) 2020-06-01 2021-12-09 Amgen Inc. Rnai constructs for inhibiting hsd17b13 expression and methods of use thereof
EP3929295A1 (de) 2020-06-26 2021-12-29 Universitat Pompeu Fabra Künstliche rnas zur modulation von rna-fragmenten
CN116194124A (zh) 2020-07-31 2023-05-30 中外制药株式会社 包含表达嵌合受体的细胞的药物组合物
IL300360A (en) 2020-08-13 2023-04-01 Amgen Inc RNAi constructs and methods to inhibit MARC1 expression
CA3199678A1 (en) 2020-11-05 2022-05-12 Amgen Inc. Methods for treating atherosclerotic cardiovascular disease with lpa-targeted rnai constructs
US20240150472A1 (en) 2021-03-17 2024-05-09 Daiichi Sankyo Company, Limited Gene coding for chimeric receptor for anti-acetylcholine receptor autoantibody
US20240366666A1 (en) 2021-04-08 2024-11-07 Phosphogam, Llc Methods and compositions for enhancing the cytotoxicity of gamma/delta-t cells
WO2023278295A1 (en) 2021-06-29 2023-01-05 The Broad Institute, Inc. Compositions and methods for ameliorating anterodorsal thalamus hyperexcitability
EP4373528A2 (de) 2021-07-19 2024-05-29 New York University Adeno-assoziierte virale vektorzusammensetzungen und verfahren zur förderung der muskelregeneration
US20250011779A1 (en) 2021-10-05 2025-01-09 Amgen Inc. Compositions and methods for enhancing gene silencing activity of oligonucleotide compounds
CN118525091A (zh) 2021-10-22 2024-08-20 安进公司 用于抑制gpam表达的rnai构建体及其使用方法
EP4269586A1 (de) 2022-04-29 2023-11-01 Johann-Wolfgang-Goethe-Universität Frankfurt am Main Targeting von mikro-rna zur behandlung von herzversagen mit konservierter ejektionsfraktion (hfpef)
CA3262515A1 (en) 2022-07-25 2024-02-01 Amgen Inc. ARNI CONSTRUCTIONS AND METHODS FOR INHIBITING FAM13A EXPRESSION
EP4353823A1 (de) 2022-10-12 2024-04-17 Resalis Therapeutics S.r.l. Inhibitoren von mikro-rna 22
UY40566A (es) 2022-12-16 2024-06-28 Amgen Inc Constructos de arni para inhibir la expresión de ttr y métodos de uso de los mismos
WO2024150525A1 (ja) 2023-01-12 2024-07-18 国立大学法人山口大学 抗ネコｐｄ－１抗体
WO2025260042A1 (en) 2024-06-14 2025-12-18 Amgen Inc. Rnai constructs and methods for inhibiting cnr1 expression
WO2026006275A2 (en) 2024-06-26 2026-01-02 Amgen Inc. Rnai constructs and methods for inhibiting expression of inhbe

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986000930A1 (en) * 1984-07-20 1986-02-13 Worcester Foundation For Experimental Biology Retroviral vaccines and vectors and methods for their construction
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
EP0737750B1 (de) * 1989-03-21 2003-05-14 Vical, Inc. Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
US5108921A (en) * 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
IL93982A0 (en) * 1989-04-03 1991-01-31 Purdue Research Foundation Method for enhancing transmembrane transport of exogenous molecules
FR2645866B1 (fr) * 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
CA2092323A1 (en) * 1990-10-01 1992-04-02 George Y. Wu Targeting viruses and cells for selective internalization by cells
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5981273A (en) * 1991-09-30 1999-11-09 Boehringer Ingelheim Int'l. Gmbh Composition comprising an endosomolytic agent for introducing nucleic acid complexes into higher eucaryotic cells
DE69333434T2 (de) * 1992-04-03 2005-03-03 The Regents Of The University Of California, Oakland Selbstorganisierendes system zur verabreichung von polynukleotiden enthaltend ein amphiphatisches peptid
WO1993024640A2 (en) * 1992-06-04 1993-12-09 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
US5284993A (en) * 1992-09-21 1994-02-08 Phillips Petroleum Company Alkylation catalyst regeneration
DK170396B1 (da) * 1993-04-20 1995-08-21 Topsoe Haldor As Fremgangsmåde til genvinding af brugt fluoreret sulfonsyrekatalysator fra en alkyleringsproces
US5614503A (en) * 1993-11-12 1997-03-25 Aronex Pharmaceuticals, Inc. Amphipathic nucleic acid transporter
DK171409B1 (da) * 1994-03-10 1996-10-21 Topsoe Haldor As Fremgangsmåde til genvinding af alkyleringskatalysatorer
US5837533A (en) * 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US6194625B1 (en) * 1994-09-30 2001-02-27 Stratco, Inc. Alkylation by controlling olefin ratios
US5650096A (en) * 1994-12-09 1997-07-22 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5910487A (en) * 1994-12-09 1999-06-08 Genzyme Corporation Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules
US5747471A (en) * 1994-12-09 1998-05-05 Genzyme Corporation Cationic amphiphiles containing steroid lipophilic groups for intracellular delivery of therapeutic molecules
US5840710A (en) * 1994-12-09 1998-11-24 Genzyme Corporation Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
US5719131A (en) * 1994-12-09 1998-02-17 Genzyme Corporation Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
US5948767A (en) * 1994-12-09 1999-09-07 Genzyme Corporation Cationic amphiphile/DNA complexes
US5767099A (en) * 1994-12-09 1998-06-16 Genzyme Corporation Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules
US5935936A (en) * 1996-06-03 1999-08-10 Genzyme Corporation Compositions comprising cationic amphiphiles and co-lipids for intracellular delivery of therapeutic molecules
US5925628A (en) * 1997-03-31 1999-07-20 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5912239A (en) * 1997-04-04 1999-06-15 Genzyme Corporation Imidazole-containing cationic amphiphiles for intracellular delivery of therapeutic molecules
US5942634A (en) * 1997-05-09 1999-08-24 Genzyme Corporation Cationic amphiphiles for cell transfections
DK26298A (da) * 1998-02-27 1999-08-28 Haldor Topsoe As Fremgangsmåde til genvinding af sulfonsyreester ud fra carbonhydridstrøm

Also Published As

Publication number Publication date
JPH10506901A (ja) 1998-07-07
US7202227B2 (en) 2007-04-10
US20050239204A1 (en) 2005-10-27
EP0789708A4 (de) 1999-12-29
US5837533A (en) 1998-11-17
ES2231791T3 (es) 2005-05-16
PT789708E (pt) 2005-03-31
US20040214328A9 (en) 2004-10-28
EP0789708A1 (de) 1997-08-20
CA2201396A1 (en) 1996-04-04
US20020155607A1 (en) 2002-10-24
EP0789708B1 (de) 2004-11-03
DE69533725D1 (de) 2004-12-09
AU3731795A (en) 1996-04-19
US6379965B1 (en) 2002-04-30
CA2201396C (en) 2010-08-24
AU704796B2 (en) 1999-05-06
DE69533725T2 (de) 2005-03-17
WO1996010038A1 (en) 1996-04-04
US6127170A (en) 2000-10-03
JP3925815B2 (ja) 2007-06-06

Similar Documents

Publication Publication Date Title
DE69533725D1 (de) Multifunktionelle molekuläre komplexe für den gen-transfer in zellen
AU5812400A (en) Carrier-drug conjugate
DE69835201D1 (en) Neoglycoproteine
CA2333732A1 (en) Redox reversible imidazole-osmium complex conjugates
CA2336634A1 (en) Antiviral macrocyclic compounds
ATE312873T1 (de) Intumeszenz-polymerzusammensetzung
WO1997025067A3 (en) Polymers
CA2223678A1 (en) Covalently linked oligonucleotide minor groove binder conjugates
MXPA02005510A (es) Compuestos, composiciones y metodos para estimular el crecimiento y alargamiento neuronal.
EP0870839A4 (de) Verfahren zur einführung von genen in zielzellen mit hilfe von retroviren
DE19983874T1 (de) Ionenempfindliche, in hartem Wasser dispergierbare Polymere und deren Verwendungen
FI840229A7 (fi) Elektronisesti johtavat polypyrrolit ja pyrrolin kopolymeerit, niitä sisältävät koostumukset, menetelmät niidevalmistamiseksi ja sähkökemialliset kennot, joissa niitä käytetään.
FR2738151B1 (fr) Antagonistes de l'activite oncogenique de la proteine mdm2, et leur utilisation dans le traitement des cancers
BR9401321A (pt) Muteína, sequência de DNA, vetor, célula, sequência de RNA composto, processo para sua preparação, composição farmacêutica e uso.
CA2295999A1 (en) Nik proteins, nucleic acids and methods
DK0815114T3 (da) Nucleinsyresyntese ved anvendelse af lysfraspaltelige beskyttende grupper
CA2382144A1 (en) Composite ion-exchange membranes
HK1046409A1 (zh) 结合趋化因子受体的杂环化合物
DE69804463D1 (de) Kationische polymere, diese kationische polymere enthaltende komplexe und wenigstens eine negative ladung enthaltende therapeutisch wirksame mittel, insbesondere nukleinsäuren und ihre verwendung in gentherapie
CA2348836A1 (en) Feed for livestock
WO2001000242A3 (en) Polycation-based bioconjugates
WO2003086273A8 (en) Histone conjugates and uses thereof
ATE221204T1 (de) Rezeptorbindungsassay, für den rezeptorbindungsassay geeigneter rekombinanter fusionsrezeptor, vektor zu dessen herstellung sowie reagenziensatz für die durchführung des rezeptorbindungsassays
AU6464699A (en) Labeling, immobilisation, enrichment, purification and detection of cells using specific domains that bind to the cell walls (cbd) of proteins binding to the drawn cell walls of viruses, bacteria or eukaryotic cells
WO1992011367A3 (en) Lipid receptors for microorganisms and corresponding adhesins, dna sequences encoding adhesins, and use thereof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0789708

Country of ref document: EP

REN Ceased due to non-payment of the annual fee